Navigation Links
Avastin Rejection Supported by Cancer Experts
Date:7/4/2011

By Steven Reinberg
HealthDay Reporter

FRIDAY, July 1 (HealthDay News) -- Oncologists and even some breast cancer support groups are endorsing a U.S. health advisory panel's recommendation that the blockbuster cancer drug Avastin be removed for use in metastatic breast cancer.

The reason: There's still a lack of understanding of how the drug works or who it helps.

Avastin was given fast-track approval by the U.S. Food and Drug Administration in 2008 to be used, in combination with the chemotherapy drug Taxol, by women with metastatic HER2-negative breast cancer.

But a six-member FDA panel of cancer experts said Wednesday that the drug was not effective, caused dangerous side effects and its approval should be revoked.

The decision, which is non-binding, came at the end of a two-day hearing granted to Avastin maker Genentech after the FDA recommended last December revoking the drug's approval for metastatic breast cancer. The FDA cited the medication's poor performance in follow-up studies and its potential for serious side effects.

Karuna Jaggar, executive director of Breast Cancer Action, told HealthDay that "the panel made the right decision. We have been advocating for the FDA to take a critical stand on Avastin and really focus on overall survival," which hasn't been proven by any of the drug's studies so far.

Dr. Paula Klein, an oncologist specializing in breast cancer at Beth Israel Medical Center in New York City, said there may well be a subset of women for whom Avastin will extend life. But she faulted the drug maker for not trying to identify that group. "What Genentech has failed to do is spend the money necessary to find the subset of breast cancer patients that will benefit," she said.

Jaggar said she wished the evidence supporting Avastin had been stronger. She said she would support having Genentech doing a trial to try to identify women who would benefit from the
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Panel Rejects Avastin for Breast Cancer
2. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
3. NIH study finds Avastin and Lucentis are equally effective in treating AMD
4. More Evidence Cancer Drug Avastin May Cause Harm
5. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
6. FDA Advises Against Avastin as Treatment for Breast Cancer
7. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
8. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
9. Romantic Rejection May Hurt Just Like Physical Pain
10. Gift-Giving, for Many Men, Means Avoiding Rejection
11. UCLA team uncovers mechanism behind organ transplant rejection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... research at Washington University School of Medicine in St. ... in males and frequently are more harmful than similar ... malignant brain tumors, are diagnosed twice as often in ... do not survive as long. , The researchers found ... cancer risk, is significantly less active in male brain ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... Urges Senate to Quickly Pass this Important Lifesaving ... Connor, American Lung Association President and CEO:Today in ... in favor with a strong bipartisan majority for ... the Family Smoking Prevention and Tobacco Control Act ...
... Finding could steer caregivers away from situations that would add ... levels of a stress hormone may be responsible for the ... children with a certain type of autism. , ... not experience the normal twofold increase of cortisol upon waking ...
... CITY, Mo., April 2 Argus Health Systems, Inc., ... received an award from the Flaspohler Research Group as ... of Interest" in the 2008 PBM Survey of ... ranked by survey participants based on specific attributes, including ...
... know where and when patients and staff interact, giving ... influenza transmission patternsATLANTA, April 2 Radianse, Inc. today ... University Hospital Midtown, Atlanta, is using the Radianse ... know early and reliably where, when and with whom ...
... 2009 Can we always see what is in front of ... and Cognitive Neuroscience at The City College of New York (CCNY), ... Journal of Neuroscience " by Professor Ro and colleagues from the ... brainwave activity is in a trough. , "We may have our ...
... (omega-3s), namely EPA and DHA found in seafood and ... benefits, but evidence of other benefits continues to stack ... menopausal women and healthier weight loss in obese dieters ... these topics are summarized in the March 2009 ...
Cached Medicine News:Health News:U.S. House of Representatives Again Votes with a Strong Bipartisan Majority in Favor of Granting the U.S. FDA Regulatory Control Over Tobacco Products 2Health News:Asperger Syndrome Tied to Low Cortisol Levels 2Health News:Argus Honored by Flaspohler Research Group as Highest-Rated PBM for 'No Conflicts of Interest' 2Health News:Radianse Announces Real-Time Tracking of Emory ED Staff and Patients to Trace and Contain Infectious Disease Spread 2Health News:Neuroscientists demonstrate link between brainwave acticity and visual perception 2Health News:Omega-3s May Benefit Newborns, Menopausal Women and Obese Individuals 2
(Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
(Date:8/1/2014)... , Aug. 1, 2014 MGC Diagnostics ... company, announced today that it has completed its ... of cardiorespiratory diagnostic products based in Sorinnes, ... served the European cardiorespiratory diagnostics market since 1977. ... of approximately €4.7 million ($6.3 million) and incurred ...
(Date:8/1/2014)... 1, 2014  Neuland Laboratories Ltd., (NSE:NEULANDLAB; BSE-Scrip ... ingredients (APIs), complex intermediates and custom ... countries, today announced financial results for the first ... 30, 2014. "Neuland,s results in the ... to accommodate certain customer needs, and we do ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... presented at Israel Society of Nephrology Conference ... months from single treatment - Data continue to ... expensive injections MISGAV, Israel and LONDON, March 27 ... latest, encouraging results of the Company,s ongoing EPODURE Biopump ...
... of Clinical Lipidology publishes largest study comparing cancer ... using FDA database -BOSTON, March 25 A ... ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to ... The study, conducted by Tufts Medical Center ...
Cached Medicine Technology:Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0454....
Medicine Products: